{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:30:12Z","timestamp":1791304212667,"version":"4.3.1"},"reference-count":147,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["tuberculosisjournal.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Tuberculosis"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.tube.2016.02.005","type":"journal-article","created":{"date-parts":[[2016,2,28]],"date-time":"2016-02-28T13:26:14Z","timestamp":1456665974000},"page":"30-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Mycobacterium tuberculosis infection and vaccine development"],"prefix":"10.1016","volume":"98","author":[{"given":"Jiansong","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing-Cheong","family":"Yam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.tube.2016.02.005_bib1","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/ng.2744","article-title":"Out-of-Africa migration and neolithic coexpansion of Mycobacterium tuberculosis with modern humans","volume":"45","author":"Comas","year":"2013","journal-title":"Nat Genet"},{"issue":"12","key":"10.1016\/j.tube.2016.02.005_bib2","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nrmicro2236","article-title":"The spectrum of latent tuberculosis: rethinking the biology and intervention strategies","volume":"7","author":"Barry","year":"2009","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.tube.2016.02.005_bib3","series-title":"Global tuberculosis report 2015","author":"WHO","year":"2015"},{"issue":"7","key":"10.1016\/j.tube.2016.02.005_bib4","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.282.7.677","article-title":"Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO global surveillance and monitoring project","volume":"282","author":"Dye","year":"1999","journal-title":"Jama"},{"key":"10.1016\/j.tube.2016.02.005_bib5","series-title":"Global tuberculosis report 2014","author":"WHO","year":"2014"},{"issue":"7","key":"10.1016\/j.tube.2016.02.005_bib6","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJM199002153220702","article-title":"Racial differences in susceptibility to infection by Mycobacterium tuberculosis","volume":"322","author":"Stead","year":"1990","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.tube.2016.02.005_bib7","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/cid\/cir378","article-title":"Racial differences in tuberculosis infection in United States communities: the coronary artery risk development in young adults study","volume":"53","author":"Nahid","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tube.2016.02.005_bib8","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1164\/ajrccm\/147.5.1311","article-title":"When tuberculosis treatment fails","volume":"147","author":"Sumartojo","year":"1993","journal-title":"Am Rev Respir Dis"},{"issue":"9728","key":"10.1016\/j.tube.2016.02.005_bib9","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/S0140-6736(10)60410-2","article-title":"Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis","volume":"375","author":"Gandhi","year":"2010","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.tube.2016.02.005_bib10","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1099\/jmm.0.05223-0","article-title":"Detection of katG Ser315Thr substitution in respiratory specimens from patients with isoniazid-resistant Mycobacterium tuberculosis using PCR-RFLP","volume":"52","author":"Leung","year":"2003","journal-title":"J\u00a0Med Microbiol"},{"issue":"2","key":"10.1016\/j.tube.2016.02.005_bib11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijantimicag.2009.09.022","article-title":"Rapid diagnosis of multidrug-resistant smear-positive pulmonary tuberculosis","volume":"35","author":"Lau","year":"2010","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"10.1016\/j.tube.2016.02.005_bib12","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1128\/AAC.50.3.1075-1078.2006","article-title":"Molecular characterization of isoniazid resistance in Mycobacterium tuberculosis: identification of a novel mutation in inhA","volume":"50","author":"Leung","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.tube.2016.02.005_bib13","first-page":"1205","volume":"34","author":"WHO","year":"2013","journal-title":"Tuberc Saudi Med J"},{"issue":"5","key":"10.1016\/j.tube.2016.02.005_bib14","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1164\/rccm.200308-1101OC","article-title":"Cough-generated aerosols of Mycobacterium tuberculosis: a new method to study infectiousness","volume":"169","author":"Fennelly","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.tube.2016.02.005_bib15","first-page":"11","article-title":"On the mechanics of droplet nuclei infection; quantitative experimental air-borne tuberculosis in rabbits","volume":"47","author":"Wells","year":"1948","journal-title":"Am J Hyg"},{"issue":"7","key":"10.1016\/j.tube.2016.02.005_bib16","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.cell.2014.11.024","article-title":"Host evasion and exploitation schemes of Mycobacterium tuberculosis","volume":"159","author":"Cambier","year":"2014","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.tube.2016.02.005_bib17","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1128\/IAI.01515-07","article-title":"Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates","volume":"76","author":"Via","year":"2008","journal-title":"Infect Immun"},{"issue":"6","key":"10.1016\/j.tube.2016.02.005_bib18","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/nprot.2013.068","article-title":"Evaluation of the pathogenesis and treatment of Mycobacterium marinum infection in zebrafish","volume":"8","author":"Takaki","year":"2013","journal-title":"Nat Protoc"},{"issue":"2","key":"10.1016\/j.tube.2016.02.005_bib19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00430-012-0278-6","article-title":"Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines","volume":"202","author":"Prabowo","year":"2013","journal-title":"Med Microbiol Immunol"},{"issue":"3","key":"10.1016\/j.tube.2016.02.005_bib20","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.chom.2012.07.009","article-title":"Neutrophils exert protection in the early tuberculous granuloma by oxidative killing of mycobacteria phagocytosed from infected macrophages","volume":"12","author":"Yang","year":"2012","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.tube.2016.02.005_bib21","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3389\/fimmu.2013.00120","article-title":"The role of the innate immune system in granulomatous disorders","volume":"4","author":"Petersen","year":"2013","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.tube.2016.02.005_bib22","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1128\/IAI.69.3.1722-1728.2001","article-title":"Temporal and spatial arrangement of lymphocytes within lung granulomas induced by aerosol infection with Mycobacterium tuberculosis","volume":"69","author":"Gonzalez-Juarrero","year":"2001","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.tube.2016.02.005_bib23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nrmicro1538","article-title":"Who puts the tubercle in tuberculosis?","volume":"5","author":"Russell","year":"2007","journal-title":"Nat Rev Microbiol"},{"issue":"3","key":"10.1016\/j.tube.2016.02.005_bib24","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/mi.2011.14","article-title":"Macrophages and control of granulomatous inflammation in tuberculosis","volume":"4","author":"Flynn","year":"2011","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.tube.2016.02.005_bib25","doi-asserted-by":"crossref","first-page":"814943","DOI":"10.1155\/2011\/814943","article-title":"Pathogenesis, immunology, and diagnosis of latent Mycobacterium tuberculosis infection","volume":"2011","author":"Ahmad","year":"2011","journal-title":"Clin Dev Immunol"},{"issue":"1","key":"10.1016\/j.tube.2016.02.005_bib26","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2008.11.014","article-title":"The role of the granuloma in expansion and dissemination of early tuberculous infection","volume":"136","author":"Davis","year":"2009","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.tube.2016.02.005_bib27","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/imr.12273","article-title":"Adventures within the speckled band: heterogeneity, angiogenesis, and balanced inflammation in the tuberculous granuloma","volume":"264","author":"Matty","year":"2015","journal-title":"Immunol Rev"},{"issue":"4","key":"10.1016\/j.tube.2016.02.005_bib28","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10875-007-9084-0","article-title":"Host innate immune response to Mycobacterium tuberculosis","volume":"27","author":"Bhatt","year":"2007","journal-title":"J\u00a0Clin Immunol"},{"issue":"1","key":"10.1016\/j.tube.2016.02.005_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1084\/jem.142.1.1","article-title":"Phagosome-lysosome interactions in cultured macrophages infected with virulent tubercle bacilli. Reversal of the usual nonfusion pattern and observations on bacterial survival","volume":"142","author":"Armstrong","year":"1975","journal-title":"J\u00a0Exp Med"},{"issue":"1","key":"10.1016\/j.tube.2016.02.005_bib30","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1128\/IAI.67.1.74-79.1999","article-title":"Mycobacterium tuberculosis catalase and peroxidase activities and resistance to oxidative killing in human monocytes in\u00a0vitro","volume":"67","author":"Manca","year":"1999","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.tube.2016.02.005_bib31","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/mi.2011.3","article-title":"Apoptosis is an innate defense function of macrophages against Mycobacterium tuberculosis","volume":"4","author":"Behar","year":"2011","journal-title":"Mucosal Immunol"},{"issue":"10","key":"10.1016\/j.tube.2016.02.005_bib32","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1128\/CVI.00190-07","article-title":"Molecular characterization of clinical isolates of Mycobacterium tuberculosis and their association with phenotypic virulence in human macrophages","volume":"14","author":"Wong","year":"2007","journal-title":"Clin Vaccine Immunol"},{"issue":"3","key":"10.1016\/j.tube.2016.02.005_bib33","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/QCO.0b013e3282f88b5d","article-title":"Mycobacterial interaction with innate receptors: TLRs, C-type lectins, and NLRs","volume":"21","author":"Jo","year":"2008","journal-title":"Curr Opin Infect Dis"},{"issue":"4","key":"10.1016\/j.tube.2016.02.005_bib34","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1128\/IAI.63.4.1491-1497.1995","article-title":"Human T-cell responses to secreted antigen fractions of Mycobacterium tuberculosis","volume":"63","author":"Boesen","year":"1995","journal-title":"Infect Immun"},{"issue":"Suppl.\u00a02","key":"10.1016\/j.tube.2016.02.005_bib35","doi-asserted-by":"crossref","first-page":"ii54","DOI":"10.1136\/ard.61.suppl_2.ii54","article-title":"Protection against tuberculosis: cytokines, T cells, and macrophages","volume":"61","author":"Kaufmann","year":"2002","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.tube.2016.02.005_bib36","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1128\/IAI.68.6.3269-3274.2000","article-title":"Identification and characterization of murine cytotoxic T cells that kill Mycobacterium tuberculosis","volume":"68","author":"Silva","year":"2000","journal-title":"Infect Immun"},{"issue":"12","key":"10.1016\/j.tube.2016.02.005_bib37","doi-asserted-by":"crossref","first-page":"8047","DOI":"10.4049\/jimmunol.0801592","article-title":"Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells","volume":"182","author":"Lindenstr\u00f8m","year":"2009","journal-title":"J\u00a0Immunol"},{"issue":"5","key":"10.1016\/j.tube.2016.02.005_bib38","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1056\/NEJM199902043400507","article-title":"Tuberculosis in patients with human immunodeficiency virus infection","volume":"340","author":"Havlir","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.tube.2016.02.005_bib39","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3389\/fimmu.2014.00180","article-title":"Functional signatures of human CD4 and CD8 T Cell responses to Mycobacterium tuberculosis","volume":"5","author":"Prezzemolo","year":"2014","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.tube.2016.02.005_bib40","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/7701","article-title":"A\u00a0human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection","volume":"21","author":"Jouanguy","year":"1999","journal-title":"Nat Genet"},{"issue":"26","key":"10.1016\/j.tube.2016.02.005_bib41","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1056\/NEJM199612263352604","article-title":"Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette\u2013Guerin infection","volume":"335","author":"Jouanguy","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.tube.2016.02.005_bib42","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1517\/14656566.5.3.581","article-title":"The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview","volume":"5","author":"Toussirot","year":"2004","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"10.1016\/j.tube.2016.02.005_bib43","first-page":"185","article-title":"Clinical and immune responses of tuberculosis patients treated with low-dose IL-2 and multidrug therapy","volume":"1","author":"Johnson","year":"1995","journal-title":"Cytokines Mol Ther"},{"issue":"16","key":"10.1016\/j.tube.2016.02.005_bib44","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1016\/j.vaccine.2011.02.010","article-title":"Vaccine-induced anti-tuberculosis protective immunity in mice correlates with the magnitude and quality of multifunctional CD4 T cells","volume":"29","author":"Derrick","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.tube.2016.02.005_bib45","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1146\/annurev.immunol.021908.132723","article-title":"Regulatory T cells in the control of host-microorganism interactions (*)","volume":"27","author":"Belkaid","year":"2009","journal-title":"Annu Rev Immunol"},{"issue":"7","key":"10.1016\/j.tube.2016.02.005_bib46","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1164\/rccm.200508-1294OC","article-title":"Regulatory T cells are expanded in blood and disease sites in patients with tuberculosis","volume":"173","author":"Guyot-Revol","year":"2006","journal-title":"Am J Respir Crit care Med"},{"issue":"8","key":"10.1016\/j.tube.2016.02.005_bib47","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1172\/JCI32933","article-title":"New TB vaccines: is there a requirement for CD8+ T cells?","volume":"117","author":"Boom","year":"2007","journal-title":"J\u00a0Clin Invest"},{"issue":"5386","key":"10.1016\/j.tube.2016.02.005_bib48","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1126\/science.282.5386.121","article-title":"An antimicrobial activity of cytolytic T cells mediated by granulysin","volume":"282","author":"Stenger","year":"1998","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.tube.2016.02.005_bib49","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1146\/annurev.immunol.18.1.275","article-title":"CD8+ T cell effector mechanisms in resistance to infection","volume":"18","author":"Harty","year":"2000","journal-title":"Annu Rev Immunol"},{"issue":"9","key":"10.1016\/j.tube.2016.02.005_bib50","doi-asserted-by":"crossref","first-page":"5299","DOI":"10.1073\/pnas.95.9.5299","article-title":"Mycobacterium bovis bacille Calmette\u2013Guerin strains secreting listeriolysin of Listeria monocytogenes","volume":"95","author":"Hess","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.tube.2016.02.005_bib51","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1093\/infdis\/165.3.506","article-title":"\u03b3\u03b4 T lymphocytes in human tuberculosis","volume":"165","author":"Barnes","year":"1992","journal-title":"J\u00a0Infect Dis"},{"issue":"6","key":"10.1016\/j.tube.2016.02.005_bib52","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1128\/IAI.71.6.3076-3087.2003","article-title":"T-cell responses to CD1-presented lipid antigens in humans with Mycobacterium tuberculosis infection","volume":"71","author":"Ulrichs","year":"2003","journal-title":"Infect Immun"},{"issue":"26","key":"10.1016\/j.tube.2016.02.005_bib53","doi-asserted-by":"crossref","first-page":"15688","DOI":"10.1073\/pnas.95.26.15688","article-title":"A\u00a0mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival","volume":"95","author":"Teitelbaum","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.tube.2016.02.005_bib54","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/978-1-4614-6111-1_12","article-title":"The role of B cells and humoral immunity in Mycobacterium tuberculosis infection","volume":"783","author":"Kozakiewicz","year":"2013","journal-title":"Adv Exp Med Biol"},{"issue":"17\u201319","key":"10.1016\/j.tube.2016.02.005_bib55","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1016\/S0264-410X(00)00519-3","article-title":"Tuberculosis subunit vaccine development: on the role of interferon-gamma","volume":"19","author":"Agger","year":"2001","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.tube.2016.02.005_bib56","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/imm.12006","article-title":"Protection conferred by heterologous vaccination against tuberculosis is dependent on the ratio of CD4(+)\/CD4(+) Foxp3(+) cells","volume":"137","author":"Fedatto","year":"2012","journal-title":"Immunology"},{"issue":"8","key":"10.1016\/j.tube.2016.02.005_bib57","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nrmicro1211","article-title":"The success and failure of BCG\u2014implications for a novel tuberculosis vaccine","volume":"3","author":"Andersen","year":"2005","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"10.1016\/j.tube.2016.02.005_bib58","first-page":"53","article-title":"History of BCG vaccine","volume":"8","author":"Luca","year":"2013","journal-title":"Maedica"},{"issue":"3","key":"10.1016\/j.tube.2016.02.005_bib59","first-page":"200","article-title":"Does the efficacy of BCG decline with time since vaccination?","volume":"2","author":"Sterne","year":"1998","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"10.1016\/j.tube.2016.02.005_bib60","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.tube.2013.12.006","article-title":"Non-tuberculous mycobacteria have diverse effects on BCG efficacy against Mycobacterium tuberculosis","volume":"94","author":"Poyntz","year":"2014","journal-title":"Tuberculosis"},{"issue":"1","key":"10.1016\/j.tube.2016.02.005_bib61","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.vaccine.2006.07.020","article-title":"The risk of disseminated Bacille Calmette\u2013Guerin (BCG) disease in HIV-infected children","volume":"25","author":"Hesseling","year":"2007","journal-title":"Vaccine"},{"issue":"21","key":"10.1016\/j.tube.2016.02.005_bib62","first-page":"181","article-title":"Meeting of the immunization Strategic Advisory Group of Experts, April 2007: conclusions and recommendations","volume":"82","author":"Strategic Advisory Group of Experts","year":"2007","journal-title":"Wkly Epidemiol Rec"},{"issue":"2","key":"10.1016\/j.tube.2016.02.005_bib63","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.smim.2013.04.006","article-title":"Tuberculosis vaccines: time to think about the next generation","volume":"25","author":"Kaufmann","year":"2013","journal-title":"Semin Immunol"},{"issue":"25","key":"10.1016\/j.tube.2016.02.005_bib64","doi-asserted-by":"crossref","first-page":"13853","DOI":"10.1073\/pnas.250480397","article-title":"Recombinant bacillus Calmette\u2013Gu\u00e9rin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model","volume":"97","author":"Horwitz","year":"2000","journal-title":"Proc Natl Acad Sci"},{"issue":"9","key":"10.1016\/j.tube.2016.02.005_bib65","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.vaccine.2012.12.053","article-title":"Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial","volume":"31","author":"Grode","year":"2013","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.tube.2016.02.005_bib66","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nm859","article-title":"Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis","volume":"9","author":"Pym","year":"2003","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.tube.2016.02.005_bib67","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nm.2285","article-title":"A\u00a0multistage tuberculosis vaccine that confers efficient protection before and after exposure","volume":"17","author":"Aagaard","year":"2011","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.tube.2016.02.005_bib68","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.4049\/jimmunol.171.3.1602","article-title":"Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette\u2013Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara","volume":"171","author":"Goonetilleke","year":"2003","journal-title":"J\u00a0Immunol"},{"issue":"3","key":"10.1016\/j.tube.2016.02.005_bib69","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.tube.2006.01.024","article-title":"RUTI: a new chance to shorten the treatment of latent tuberculosis infection","volume":"86","author":"Cardona","year":"2006","journal-title":"Tuberculosis"},{"issue":"4","key":"10.1016\/j.tube.2016.02.005_bib70","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1086\/315393","article-title":"Randomized controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodeficiency virus-infected ugandan adults with newly diagnosed pulmonary tuberculosis. The Uganda-Case Western Reserve University Research Collaboration","volume":"181","author":"Johnson","year":"2000","journal-title":"J\u00a0Infect Dis"},{"issue":"7","key":"10.1016\/j.tube.2016.02.005_bib71","doi-asserted-by":"crossref","first-page":"e39215","DOI":"10.1371\/journal.pone.0039215","article-title":"Efficacy of Mycobacterium indicus pranii immunotherapy as an adjunct to chemotherapy for tuberculosis and underlying immune responses in the lung","volume":"7","author":"Gupta","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.tube.2016.02.005_bib72","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1073\/pnas.92.5.1530","article-title":"Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis","volume":"92","author":"Horwitz","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.tube.2016.02.005_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2014.00152","article-title":"Recombinant BCG: innovations on an old vaccine. Scope of BCG strains and strategies to improve long-lasting memory","volume":"5","author":"Costa da","year":"2014","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.tube.2016.02.005_bib74","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1172\/JCI24617","article-title":"Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette\u2013Guerin mutants that secrete listeriolysin","volume":"115","author":"Grode","year":"2005","journal-title":"J\u00a0Clin Invest"},{"issue":"10","key":"10.1016\/j.tube.2016.02.005_bib75","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/infdis\/jir592","article-title":"Recombinant BCG DeltaureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses","volume":"204","author":"Desel","year":"2011","journal-title":"J\u00a0Infect Dis"},{"issue":"1","key":"10.1016\/j.tube.2016.02.005_bib76","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1086\/345862","article-title":"Deletion of RD1 from Mycobacterium tuberculosis mimics bacille Calmette\u2013Guerin attenuation","volume":"187","author":"Lewis","year":"2003","journal-title":"J\u00a0Infect Dis"},{"issue":"7","key":"10.1016\/j.tube.2016.02.005_bib77","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2471\/BLT.08.055657","article-title":"Disseminated bacille Calmette\u2013Gu\u00e9rin disease in HIV-infected South African infants","volume":"87","author":"Hesseling","year":"2009","journal-title":"Bull World Health Organ"},{"issue":"29","key":"10.1016\/j.tube.2016.02.005_bib78","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1016\/j.vaccine.2005.03.001","article-title":"New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development","volume":"23","author":"Kamath","year":"2005","journal-title":"Vaccine"},{"issue":"42","key":"10.1016\/j.tube.2016.02.005_bib79","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1016\/j.vaccine.2013.07.051","article-title":"Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials","volume":"31","author":"Arbues","year":"2013","journal-title":"Vaccine"},{"issue":"20","key":"10.1016\/j.tube.2016.02.005_bib80","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1016\/j.vaccine.2010.02.094","article-title":"Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers","volume":"28","author":"Dissel van","year":"2010","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.tube.2016.02.005_bib81","doi-asserted-by":"crossref","first-page":"e114602","DOI":"10.1371\/journal.pone.0114602","article-title":"Safety and immunogenicity of H1\/IC31(R), an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells\/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial","volume":"9","author":"Reither","year":"2014","journal-title":"PLoS One"},{"issue":"52","key":"10.1016\/j.tube.2016.02.005_bib82","doi-asserted-by":"crossref","first-page":"7098","DOI":"10.1016\/j.vaccine.2014.10.036","article-title":"A\u00a0novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human","volume":"32","author":"Dissel van","year":"2014","journal-title":"Vaccine"},{"issue":"30","key":"10.1016\/j.tube.2016.02.005_bib83","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1016\/j.vaccine.2015.05.036","article-title":"The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: a randomized controlled trial","volume":"33","author":"Geldenhuys","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.tube.2016.02.005_bib84","unstructured":"A Randomized, Placebo Controlled, Partially Blinded Phase II Study to Evaluate Safety, Immunogenicity, and Prevention of Infection With Mycobacterium Tuberculosis of AERAS-404 and BCG Revaccination in Healthy Adolescents (040-404). Available from: http:\/\/clinicaltrials.gov\/show\/NCT02075203."},{"key":"10.1016\/j.tube.2016.02.005_bib85","unstructured":"Phase 1\/II, Safety and Immunogenicity Study of AERAS-404 in BCG-Primed Infants (C-015-404). Available from: http:\/\/clinicaltrials.gov\/show\/NCT01861730."},{"key":"10.1016\/j.tube.2016.02.005_bib86","unstructured":"A Phase I\/IIa Safety & Immunogenicity of AERAS-456 in HIV-Negative Adults With & Without Latent Tuberculosis Infection (C-035-456). Available from: http:\/\/clinicaltrials.gov\/show\/NCT01865487."},{"issue":"17","key":"10.1016\/j.tube.2016.02.005_bib87","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/j.vaccine.2012.05.035","article-title":"Improved CD4+ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72\/AS01 as compared to the M72\/AS02 and Mtb72F\/AS02 tuberculosis candidate vaccine formulations: a randomized trial","volume":"31","author":"Leroux-Roels","year":"2013","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.tube.2016.02.005_bib88","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/nm1128","article-title":"Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans","volume":"10","author":"McShane","year":"2004","journal-title":"Nat Med"},{"issue":"9871","key":"10.1016\/j.tube.2016.02.005_bib89","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","article-title":"Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial","volume":"381","author":"Tameris","year":"2013","journal-title":"Lancet"},{"issue":"205","key":"10.1016\/j.tube.2016.02.005_bib90","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006843","article-title":"A\u00a0human type 5 adenovirus\u2013based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity","volume":"5","author":"Smaill","year":"2013","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1016\/j.tube.2016.02.005_bib91","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1164\/rccm.200910-1484OC","article-title":"The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults","volume":"181","author":"Abel","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"1 Suppl.","key":"10.1016\/j.tube.2016.02.005_bib92","article-title":"Adenoviral-vectored tuberculosis vaccine AERAS-402 enhances T cell cytokine response in TB+ patients. (VAC12P. 1026)","volume":"192","author":"Graves","year":"2014","journal-title":"J\u00a0Immunol"},{"issue":"1 Suppl.","key":"10.1016\/j.tube.2016.02.005_bib93","article-title":"Heterologous prime-boost with Ad35\/AERAS-402 and MVA85A elicits potent CD8+ T cell immune responses in a phase I clinical trial (VAC7P. 969)","volume":"192","author":"Hokey","year":"2014","journal-title":"J\u00a0Immunol"},{"issue":"5","key":"10.1016\/j.tube.2016.02.005_bib94","doi-asserted-by":"crossref","first-page":"e20404","DOI":"10.1371\/journal.pone.0020404","article-title":"Prophylactic effect of a therapeutic vaccine against TB based on fragments of Mycobacterium tuberculosis","volume":"6","author":"Vilaplana","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.tube.2016.02.005_bib95","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.vaccine.2009.09.134","article-title":"Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI","volume":"28","author":"Vilaplana","year":"2010","journal-title":"Vaccine"},{"issue":"16","key":"10.1016\/j.tube.2016.02.005_bib96","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1097\/00002030-200311070-00010","article-title":"Immunogenicity of an inactivated mycobacterial vaccine for the prevention of HIV-associated tuberculosis: a randomized, controlled trial","volume":"17","author":"Vuola","year":"2003","journal-title":"Aids"},{"issue":"9","key":"10.1016\/j.tube.2016.02.005_bib97","doi-asserted-by":"crossref","first-page":"e23826","DOI":"10.1371\/journal.pone.0023826","article-title":"Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: a meta-analysis","volume":"6","author":"Yang","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.tube.2016.02.005_bib98","unstructured":"Phase III Clinical Study of Efficacy and Safety of Vaccae\u2122 to Prevent Tuberculosis. Available from: http:\/\/clinicaltrials.gov\/show\/NCT01979900."},{"key":"10.1016\/j.tube.2016.02.005_bib99","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001166","article-title":"Mycobacterium vaccae immunotherapy for treating tuberculosis","volume":"1","author":"Bruyn de","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.tube.2016.02.005_bib100","unstructured":"Efficacy and Safety Study of Immunomodulator as an Adjunct Therapy in Pulmonary Tuberculosis (TB) Retreatment Patients. Available from: http:\/\/clinicaltrials.gov\/show\/NCT00265226."},{"issue":"1","key":"10.1016\/j.tube.2016.02.005_bib101","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1365-2958.2001.02500.x","article-title":"An essential role for phoP in Mycobacterium tuberculosis virulence","volume":"41","author":"Perez","year":"2001","journal-title":"Mol Microbiol"},{"issue":"17","key":"10.1016\/j.tube.2016.02.005_bib102","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1016\/j.vaccine.2006.03.017","article-title":"The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs","volume":"24","author":"Cardona","year":"2006","journal-title":"Vaccine"},{"issue":"18","key":"10.1016\/j.tube.2016.02.005_bib103","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1016\/j.vaccine.2009.02.060","article-title":"Extended safety studies of the attenuated live tuberculosis vaccine SO2 based on phoP mutant","volume":"27","author":"Cardona","year":"2009","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.tube.2016.02.005_bib104","doi-asserted-by":"crossref","first-page":"e5264","DOI":"10.1371\/journal.pone.0005264","article-title":"MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques","volume":"4","author":"Verreck","year":"2009","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.tube.2016.02.005_bib105","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1128\/IAI.73.2.1196-1203.2005","article-title":"Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis","volume":"73","author":"Sambandamurthy","year":"2005","journal-title":"Infect Immun"},{"issue":"34","key":"10.1016\/j.tube.2016.02.005_bib106","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1016\/j.vaccine.2009.05.050","article-title":"Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates","volume":"27","author":"Larsen","year":"2009","journal-title":"Vaccine"},{"issue":"37\u201339","key":"10.1016\/j.tube.2016.02.005_bib107","doi-asserted-by":"crossref","first-page":"6309","DOI":"10.1016\/j.vaccine.2006.05.097","article-title":"Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis","volume":"24","author":"Sambandamurthy","year":"2006","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.tube.2016.02.005_bib108","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/nm.2420","article-title":"A\u00a0recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis","volume":"17","author":"Sweeney","year":"2011","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.tube.2016.02.005_bib109","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1128\/IAI.69.5.2773-2778.2001","article-title":"Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6","volume":"69","author":"Weinrich Olsen","year":"2001","journal-title":"Infect Immun"},{"issue":"8","key":"10.1016\/j.tube.2016.02.005_bib110","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/mt.2009.130","article-title":"New insights on adenovirus as vaccine vectors","volume":"17","author":"Lasaro","year":"2009","journal-title":"Mol Ther"},{"issue":"5","key":"10.1016\/j.tube.2016.02.005_bib111","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1128\/IAI.69.5.2773-2778.2001","article-title":"Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85B and ESAT-6","volume":"69","author":"Olsen","year":"2001","journal-title":"Infect Immun"},{"issue":"10","key":"10.1016\/j.tube.2016.02.005_bib112","doi-asserted-by":"crossref","first-page":"6148","DOI":"10.1128\/IAI.72.10.6148-6150.2004","article-title":"Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model","volume":"72","author":"Olsen","year":"2004","journal-title":"Infect Immun"},{"issue":"21","key":"10.1016\/j.tube.2016.02.005_bib113","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1016\/j.vaccine.2004.11.051","article-title":"Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6","volume":"23","author":"Langermans","year":"2005","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.tube.2016.02.005_bib114","doi-asserted-by":"crossref","first-page":"6332","DOI":"10.4049\/jimmunol.174.10.6332","article-title":"Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy","volume":"174","author":"Dietrich","year":"2005","journal-title":"J\u00a0Immunol"},{"issue":"9","key":"10.1016\/j.tube.2016.02.005_bib115","doi-asserted-by":"crossref","first-page":"6353","DOI":"10.4049\/jimmunol.177.9.6353","article-title":"Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette\u2013Guerin immunity","volume":"177","author":"Dietrich","year":"2006","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.tube.2016.02.005_bib116","series-title":"A\u00a0phase I trial of a LTK63 adjuvated tuberculosis Nasal subunit vaccine (Ag85B-ESAT6) (TMUVA-01)","author":"St George's University of London","year":"2008"},{"issue":"4","key":"10.1016\/j.tube.2016.02.005_bib117","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.vaccine.2009.10.114","article-title":"Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen","volume":"28","author":"Skeiky","year":"2010","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.tube.2016.02.005_bib118","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1046\/j.1365-2958.2002.02779.x","article-title":"Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling","volume":"43","author":"Betts","year":"2002","journal-title":"Mol Microbiol"},{"issue":"1","key":"10.1016\/j.tube.2016.02.005_bib119","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1172\/JCI46252","article-title":"The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection","volume":"122","author":"Lin","year":"2012","journal-title":"J\u00a0Clin Invest"},{"issue":"12","key":"10.1016\/j.tube.2016.02.005_bib120","doi-asserted-by":"crossref","first-page":"7618","DOI":"10.4049\/jimmunol.172.12.7618","article-title":"Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein","volume":"172","author":"Skeiky","year":"2004","journal-title":"J\u00a0Immunol"},{"issue":"7","key":"10.1016\/j.tube.2016.02.005_bib121","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1073\/pnas.0712077106","article-title":"Defined tuberculosis vaccine, Mtb72F\/AS02A, evidence of protection in cynomolgus monkeys","volume":"106","author":"Reed","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.tube.2016.02.005_bib122","doi-asserted-by":"crossref","first-page":"475","DOI":"10.4161\/hv.8570","article-title":"The candidate tuberculosis vaccine Mtb72F\/AS02A: tolerability and immunogenicity in humans","volume":"5","author":"Von Eschen","year":"2009","journal-title":"Hum Vaccin"},{"issue":"2","key":"10.1016\/j.tube.2016.02.005_bib123","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.tube.2012.10.011","article-title":"The candidate tuberculosis vaccine Mtb72F\/AS02 in PPD positive adults: a randomized controlled phase I\/II study","volume":"93","author":"Spertini","year":"2013","journal-title":"Tuberc (Edinb)"},{"issue":"6","key":"10.1016\/j.tube.2016.02.005_bib124","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1128\/IAI.73.6.3814-3816.2005","article-title":"Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs","volume":"73","author":"Williams","year":"2005","journal-title":"Infect Immun"},{"issue":"10","key":"10.1016\/j.tube.2016.02.005_bib125","doi-asserted-by":"crossref","first-page":"6357","DOI":"10.4049\/jimmunol.173.10.6357","article-title":"Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis","volume":"173","author":"Wang","year":"2004","journal-title":"J\u00a0Immunol"},{"issue":"8","key":"10.1016\/j.tube.2016.02.005_bib126","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1128\/IAI.00004-07","article-title":"Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon","volume":"75","author":"Radosevic","year":"2007","journal-title":"Infect Immun"},{"issue":"6","key":"10.1016\/j.tube.2016.02.005_bib127","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1172\/JCI64704","article-title":"PD1-based DNA vaccine amplifies HIV-1 GAG-specific CD8+ T cells in mice","volume":"123","author":"Zhou","year":"2013","journal-title":"J\u00a0Clin Invest"},{"issue":"21","key":"10.1016\/j.tube.2016.02.005_bib128","doi-asserted-by":"crossref","first-page":"6010","DOI":"10.1158\/0008-5472.CAN-14-0473","article-title":"Vaccine-elicited CD8+ T cells cure mesothelioma by overcoming tumor-induced immunosuppressive environment","volume":"74","author":"Tan","year":"2014","journal-title":"Cancer Res"},{"issue":"32","key":"10.1016\/j.tube.2016.02.005_bib129","doi-asserted-by":"crossref","first-page":"32426","DOI":"10.18632\/oncotarget.5856","article-title":"Antigen spreading-induced CD8+T cells confer protection against the lethal challenge of wild-type malignant mesothelioma by eliminating myeloid-derived suppressor cells","volume":"6","author":"Yu","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.tube.2016.02.005_bib130","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0065-2660(05)55002-8","article-title":"Human clinical trials of plasmid DNA vaccines","volume":"55","author":"Liu","year":"2005","journal-title":"Adv Genet"},{"issue":"5","key":"10.1016\/j.tube.2016.02.005_bib131","doi-asserted-by":"crossref","first-page":"e19252","DOI":"10.1371\/journal.pone.0019252","article-title":"In\u00a0vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers","volume":"6","author":"Vasan","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.tube.2016.02.005_bib132","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/QAI.0b013e3181651b9d","article-title":"Design, construction, and characterization of a dual-promoter multigenic DNA vaccine directed against an HIV-1 subtype C\/B' recombinant","volume":"47","author":"Huang","year":"2008","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"4","key":"10.1016\/j.tube.2016.02.005_bib133","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1172\/JCI34224","article-title":"The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells","volume":"118","author":"Nchinda","year":"2008","journal-title":"J\u00a0Clin Invest"},{"issue":"7","key":"10.1016\/j.tube.2016.02.005_bib134","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/mt.2013.63","article-title":"Potentiating functional antigen-specific CD8(+) T cell immunity by a novel PD1 isoform-based fusion DNA vaccine","volume":"21","author":"Zhou","year":"2013","journal-title":"Mol Ther"},{"issue":"11","key":"10.1016\/j.tube.2016.02.005_bib135","doi-asserted-by":"crossref","first-page":"5499","DOI":"10.4049\/jimmunol.168.11.5499","article-title":"A\u00a0rational strategy to design multiepitope immunogens based on multiple Th lymphocyte epitopes","volume":"168","author":"Livingston","year":"2002","journal-title":"J\u00a0Immunol"},{"issue":"9","key":"10.1016\/j.tube.2016.02.005_bib136","doi-asserted-by":"crossref","first-page":"5366","DOI":"10.4049\/jimmunol.166.9.5366","article-title":"Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine","volume":"166","author":"Velders","year":"2001","journal-title":"J\u00a0Immunol"},{"issue":"8","key":"10.1016\/j.tube.2016.02.005_bib137","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1093\/infdis\/jis425","article-title":"Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment","volume":"207","author":"Coler","year":"2013","journal-title":"J\u00a0Infect Dis"},{"issue":"Suppl.\u00a02","key":"10.1016\/j.tube.2016.02.005_bib138","doi-asserted-by":"crossref","first-page":"S325","DOI":"10.1093\/infdis\/jis197","article-title":"Adjunct immunotherapies for tuberculosis","volume":"205","author":"Uhlin","year":"2012","journal-title":"J\u00a0Infect Dis"},{"issue":"9173","key":"10.1016\/j.tube.2016.02.005_bib139","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0140-6736(98)10448-8","article-title":"Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: a randomised controlled trial","volume":"354","author":"Durban Immunotherapy Trial Group","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.tube.2016.02.005_bib140","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.2741\/1292","article-title":"Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis","volume":"9","author":"Stanford","year":"2004","journal-title":"Front Biosci Landmark"},{"issue":"8","key":"10.1016\/j.tube.2016.02.005_bib141","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1128\/IAI.65.8.3317-3327.1997","article-title":"Pathogenesis of tuberculosis in mice exposed to low and high doses of an environmental mycobacterial saprophyte before infection","volume":"65","author":"Hernandez-Pando","year":"1997","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.tube.2016.02.005_bib142","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1054\/tube.2001.0318","article-title":"Increased protection against bovine tuberculosis in the brushtail possum (Trichosurus vulpecula) when BCG is administered with killed Mycobacterium vaccae","volume":"82","author":"Skinner","year":"2002","journal-title":"Tuberc (Edinb)"},{"issue":"26","key":"10.1016\/j.tube.2016.02.005_bib143","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1016\/j.vaccine.2014.03.047","article-title":"Therapeutic vaccines for tuberculosis\u2013a systematic review","volume":"32","author":"Groschel","year":"2014","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.tube.2016.02.005_bib144","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0264-410X(90)90134-8","article-title":"Immunotherapeutic effects of a vaccine based on a saprophytic cultivable mycobacterium, Mycobacterium w in multibacillary leprosy patients","volume":"8","author":"Talwar","year":"1990","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.tube.2016.02.005_bib145","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1128\/IAI.00526-08","article-title":"Immunogenicity and protective efficacy of \u201cMycobacterium w\u201d against Mycobacterium tuberculosis in mice immunized with live versus heat-killed M. w by the aerosol or parenteral route","volume":"77","author":"Gupta","year":"2009","journal-title":"Infect Immun"},{"issue":"103","key":"10.1016\/j.tube.2016.02.005_bib146","article-title":"Phase 2 trial of V-5 immunitor (V5) in patients with chronic hepatitis C Co-infected with HIV and Mycobacterium tuberculosis","volume":"1","author":"Arjanova","year":"2010","journal-title":"J\u00a0Vaccines Vaccin"},{"issue":"2","key":"10.1016\/j.tube.2016.02.005_bib147","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2217\/imt.10.96","article-title":"Adjunct oral immunotherapy in patients with re-treated, multidrug-resistant or HIV-coinfected TB","volume":"3","author":"Arjanova","year":"2011","journal-title":"Immunotherapy"}],"container-title":["Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979215302973?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979215302973?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T01:39:36Z","timestamp":1600220376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1472979215302973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":147,"alternative-id":["S1472979215302973"],"URL":"https:\/\/doi.org\/10.1016\/j.tube.2016.02.005","relation":{},"ISSN":["1472-9792"],"issn-type":[{"value":"1472-9792","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mycobacterium tuberculosis infection and vaccine development","name":"articletitle","label":"Article Title"},{"value":"Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tube.2016.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}